The trial will evaluate the efficacy and safety of INGN 225 in as many as 80 patients with extensive stage SCLC at multiple centers.
Patients with SCLC have an extremely poor prognosis despite frequent initial responses to chemotherapy. p53 abnormalities occur in the majority of SCLC patients and these patients are expected to be well-suited to the testing of the clinical efficacy of INGN 225. INGN 225 is a p53 immunotherapy using a patient’s own cells to stimulate an anti-tumor immune response to fight cancer.